{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000536","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.820587+00:00","generated_at":"2026-06-26T01:45:18.603030+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Teva Q1 GAAP loss $0.86/share; revenue down 8%; cuts FY revenue guidance","bullets":["GAAP diluted loss per share $0.86 vs. income $0.07 in Q1 2021; non-GAAP EPS $0.55 vs. $0.63.","Revenue $3.66B, down 8% YoY (5% local currency); FY 2022 revenue guidance lowered to $15.4-$16.0B.","GAAP operating loss $713M driven by $1.1B opioid litigation settlement provisions.","COPAXONE revenue outlook cut to ~$750M from ~$850M; adjusted EBITDA and EPS guidance reaffirmed.","First generic Revlimid launched in US; AJOVY and AUSTEDO growing; opioid settlements with Florida and Rhode Island."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000536","json":"https://secwatch.observer/filing/0001157523-22-000536.json","markdown":"https://secwatch.observer/filing/0001157523-22-000536.md","text":"https://secwatch.observer/filing/0001157523-22-000536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752322000536/0001157523-22-000536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752322000536/a52704380.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:45:18.603030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}